-+ 0.00%
-+ 0.00%
-+ 0.00%

Aptevo Reports Tumor-Cell Killing Under Immunosuppressive Conditions in Preclinical Studies

PUBT·11/09/2026 13:31:20
Listen to the news
Aptevo Reports Tumor-Cell Killing Under Immunosuppressive Conditions in Preclinical Studies
  • Aptevo Therapeutics presented preclinical solid-tumor immunotherapy findings at the Society for Immunotherapy of Cancer meeting on November 7, 2026.
  • APVO451 and APVO452 killed tumor cells under immunosuppressive conditions, supporting further development of treatments combining CD40 activation with T-cell engagement.
  • APVO711 combined CD40 activation with PD-L1 checkpoint blockade in preclinical studies, supporting a complementary approach to overcoming tumor immune suppression.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202611090830ACCESSWRNAPR_____1248633) on November 09, 2026, and is solely responsible for the information contained therein.